## September 2022 Profile Data Summary

<table>
<thead>
<tr>
<th>Year</th>
<th>Profile</th>
<th>% Profile</th>
<th>Gender</th>
<th>Profile</th>
<th>% Profile</th>
<th>Time Having Current Implants</th>
<th>Indication</th>
<th>Profile</th>
<th>% Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>4</td>
<td>2%</td>
<td>Female</td>
<td>218</td>
<td>99.5%</td>
<td>Range Low</td>
<td>Augmentation</td>
<td>91</td>
<td>57.2%</td>
</tr>
<tr>
<td>2018</td>
<td>11</td>
<td>8%</td>
<td>Transgender</td>
<td>1</td>
<td>0.4%</td>
<td>Range High</td>
<td>Reconstruction</td>
<td>68</td>
<td>42.8%</td>
</tr>
<tr>
<td>2019</td>
<td>29</td>
<td>22%</td>
<td>Not Reported</td>
<td>21</td>
<td>9%</td>
<td>Average</td>
<td>Not Reported</td>
<td>81</td>
<td>33.8%</td>
</tr>
<tr>
<td>2020</td>
<td>54</td>
<td>41%</td>
<td>Total</td>
<td>240</td>
<td>100%</td>
<td>Median</td>
<td>Total</td>
<td>240</td>
<td>100%</td>
</tr>
<tr>
<td>2021</td>
<td>23</td>
<td>18%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2022</td>
<td>11</td>
<td>8%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date Unavailable</td>
<td>109</td>
<td>45%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>183</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>202</td>
<td>84.5%</td>
</tr>
</tbody>
</table>

### RACE Profile % Reported
- Black: 3 (1.5%)
- Multiracial: 1 (0.5%)
- White: 196 (98.0%)
- Total: 240

### Implant Fill Profile % Reported
- Saline: 115 (39.2%)
- Saline/Silicone: 6 (2.0%)
- Silicone: 178 (60.8%)
- Total: 305

### Implant Texture Profile % Reported
- Textured (Inc W/Hx of Smooth): 403 (97.8%)
- Smooth*: 7 (1.7%)
- Polyurethane: 2 (0.5%)
- Not Reported: 3 (0.7%)
- Total: 415

*Confirmed 3 previous textured implants, 1 TEXT expander; 3 to do chart review.

### Ethnicity Profile % Reported
- Hispanic: 13 (13%)
- Non-Hispanic: 86 (87%)
- Total: 240

### Adm Use Profile % Reported
- No: 152 (63%)
- Yes: 88 (37%)
- Total: 240

### Indication Profile % Reported
- Augmentation: 91 (57.2%)
- Reconstruction: 68 (42.8%)
- Not Reported: 81 (33.8%)
- Total: 240

### Systemic Symptoms Profile % Reported
- No: 198 (90.0%)
- Yes: 22 (10.0%)
- Total: 220

### Systemic Symptoms Profile % Reported
- Non-Breast Skin Lesions: 2 (0.8%)
- FEVERS: 9 (3.8%)
- Night Sweats: 10 (4.2%)
- Weight Loss: 6 (2.5%)
- Only Reported Symptom: 1 (0.4%)
- Fevers: 0 (0%)
- Night Sweats: 0 (0%)
- Weight Loss: 0 (0%)

### Local Symptoms Profile % Reported
- No: 123 (5.1%)
- Yes: 215 (94.9%)
- Total: 228

### Local Symptoms Profile % Reported
- Breast Skin Lesions: 17 (7.1%)
- Pain: 91 (37.9%)
- Redness: 27 (11.3%)
- Seroma: 179 (74.6%)
- Axillary Lymphadenopathy: 16 (6.7%)
- Breast Mass: 37 (15.4%)
- Capsular Contracture: 67 (27.9%)
- Only Reported Symptom: 1 (0.4%)
- Breast Skin Lesions Only: 1 (0.4%)
- Pain Only: 0 (0.0%)
- Redness Only: 0 (0.0%)
- Seroma Only: 14 (5.8%)
- Axillary Lymphadenopathy Only: 1 (0.4%)
- Breast Mass Only: 7 (0.8%)
- Capsular Contracture Only: 6 (2.5%)

### Time Having Current Implants
- Range Low: 0.08
- Range High: 40.09
- Average: 10.63
- Median: 9.57

---

DATE UNAVAIL: 109
RANGE (LOW): 2018
RANGE (HIGH): 2019
DATE UNAVAIL: 109
RANGE (LOW): 2018
RANGE (HIGH): 2019
DATE UNAVAIL: 109
RANGE (LOW): 2018
RANGE (HIGH): 2019
DATE UNAVAIL: 109
RANGE (LOW): 2018
RANGE (HIGH): 2019
DATE UNAVAIL: 109
RANGE (LOW): 2018
RANGE (HIGH): 2019
<table>
<thead>
<tr>
<th>Country</th>
<th>Cases</th>
<th>Deaths</th>
<th>Country</th>
<th>Cases</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Argentina</td>
<td>17</td>
<td>0</td>
<td>Malaysia</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Australia</td>
<td>112</td>
<td>4</td>
<td>Mexico</td>
<td>14</td>
<td>0</td>
</tr>
<tr>
<td>Austria</td>
<td>6</td>
<td>0</td>
<td>Netherlands</td>
<td>70</td>
<td>2</td>
</tr>
<tr>
<td>Belgium (inc. Luxembourg)</td>
<td>26</td>
<td>0</td>
<td>New Zealand</td>
<td>20</td>
<td>1</td>
</tr>
<tr>
<td>Brazil</td>
<td>31</td>
<td>1</td>
<td>Norway</td>
<td>13</td>
<td>0</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>1</td>
<td>0</td>
<td>Panama</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Canada</td>
<td>38</td>
<td>1</td>
<td>Poland</td>
<td>10</td>
<td>0</td>
</tr>
<tr>
<td>Chile</td>
<td>2</td>
<td>0</td>
<td>Portugal</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>China</td>
<td>1</td>
<td>0</td>
<td>Romania</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Colombia</td>
<td>17</td>
<td>1</td>
<td>Russia</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Croatia</td>
<td>1</td>
<td>0</td>
<td>Singapore</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>1</td>
<td>1</td>
<td>Slovenia</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Denmark</td>
<td>13</td>
<td>0</td>
<td>South Africa</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Egypt</td>
<td>1</td>
<td>0</td>
<td>South Korea</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Finland</td>
<td>17</td>
<td>0</td>
<td>Spain</td>
<td>74</td>
<td>3</td>
</tr>
<tr>
<td>France</td>
<td>99</td>
<td>4</td>
<td>Sweden</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Germany</td>
<td>30</td>
<td>0</td>
<td>Switzerland</td>
<td>11</td>
<td>0</td>
</tr>
<tr>
<td>Greece</td>
<td>1</td>
<td>0</td>
<td>Taiwan</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Hungary</td>
<td>1</td>
<td>0</td>
<td>Thailand</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Ireland</td>
<td>1</td>
<td>0</td>
<td>Turkey</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Israel</td>
<td>9</td>
<td>0</td>
<td>United Kingdom</td>
<td>78</td>
<td>1</td>
</tr>
<tr>
<td>Italy</td>
<td>73</td>
<td>2</td>
<td>United States</td>
<td>402</td>
<td>8</td>
</tr>
<tr>
<td>Japan</td>
<td>4</td>
<td>0</td>
<td>Venezuela</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

**TOTAL CASES** | 1233

**TOTAL DEATHS** | 31